In this issue of Cell, Wu et al. employed C. elegans and human cell experiments to identify a pathway through which metformin increases lifespan and inhibits growth. A key transcriptional target, ACAD10, is activated when metformin induces nuclear exclusion of the GTPase RagC, thereby inhibiting mTORC1 through an unexpected mechanism.
Metformin is the most commonly used drug for the treatment of type 2 diabetes. It is prescribed as a glucose-lowering and insulin-sensitizing agent, but a clear mechanistic understanding of its effects has remained elusive. Research toward this goal has unearthed several potential therapeutic applications. After epidemiological studies detected a lower prevalence of cancers in type 2 diabetic patients treated with this drug, subsequent reports suggested that metformin slows cancer cell growth and protects against multiple cancers (Pryor and Cabreiro, 2015) . In the current issue of Cell, Wu et al. (2016) , used the power of C. elegans genetics to conduct a series of screens that revealed an unexpected pathway of metformin action. They found that effects of metformin on mitochondrial energetics resulted in restricted transit of the RagC GTPase through the nuclear pore complex (NPC), leading to mechanistic target of rapamycin complex 1 (mTORC1) inhibition and transcriptional induction of acyl-coA dehydrogenase family member 10 (ACAD10). The new work has exciting implications for the metabolism, cancer biology, and aging fields.
Wu and colleagues started with a simple observation, that metformin treatment slows C. elegans growth, then conducted an RNA interference (RNAi) screen to look for suppression of this phenotype. They found that knockdown of the C. elegans ortholog of ACAD10, CeACAD10, provided the strongest block to the metformin growth phenotype. Previous work had shown that metformin disrupted mitochondrial energetics and inhibited the mTORC1 kinase through an unidentified mechanism (Kalender et al., 2010; Pryor and Cabreiro, 2015) . Wu et al., established that metformin acts on these processes upstream of ACAD10 transcription and C. elegans growth, thereby placing these players in the same molecular pathway (Figure 1) . Very little is known about ACAD10, but some members of the family participate in the rate-limiting step of fatty acid b-oxidation, and others are involved in amino acid catabolism. Through a proteomics approach Wu and colleagues determined that CeACAD10 interacts with proteins involved in growth, development, ribosomal, and mitochondrial function (Wu et al., 2016) , but it remains an exciting mystery how this enzyme works to regulate growth, cell viability and metabolism.
How might metformin regulate mTORC1 and ACAD10? A forward genetic screen identified two NPC members as essential for the metformin-mediated transcriptional induction of CeACAD10 and growth inhibition. Additional genetic and functional experiments revealed the hierarchy of this pathway. In NPC mutant C. elegans, CeACAD10 expression could be induced by treatment with the mTOR inhibitor rapamycin, but not by the mitochondrial complex 1 inhibitor rotenone (Wu et al., 2016) . Similar results were obtained in mammalian cells, confirming conservation of this pathway (Wu et al., 2016) . Thus, in the metformin-response pathway, altered mitochondrial energetics lies upstream of the NPC, while mTOR inhibition is downstream (Figure 1) .
A particularly interesting question remained: how does metformin regulate mTORC1 activity by acting through the NPC? Work using mammalian cells suggests that biguanides inhibit mTORC1 via the Rag family of GTPases, although through an unknown mechanism (Kalender et al., 2010). The four Rags (A or B which heterodimerize with C or D) form part of the amino acid sensing machinery that recruits mTORC1 to the lysosome, where it becomes activated (BarPeled and Sabatini, 2014; Castillo-Quan et al., 2015) . mTOR can accumulate in the perinuclear region after amino acid stimulation (Kalender et al., 2010; Sancak et al., 2008) , and indeed several components of mTORC1 pathway have been localized in or around the nucleus (Betz and Hall, 2013) . The purpose of this localization is not completely understood. Wu and colleagues determined that the metformin-related biguanide phenformin restricts nuclear access of RagC through the NPC (Wu et al., 2016) . For the Rags to activate mTORC1, they need to be in a specific nucleotide-binding conformation: RagA GTP /RagC GDP (Figure 1 ) (BarPeled and Sabatini, 2014; Castillo-Quan et al., 2015) . The authors identified the presence of folliculin (a previously identified RagC GTPase-activating protein) in the nucleus that allows RagC to acquire its active GDP-loaded status. They went on to determine that the dominant trigger of RagC nuclear localization is an inactivated RagA (RagA GDP ), which drives RagC to the nucleus (Wu et al., 2016) . By restricting nuclear activation of RagC, biguanides inhibit mTORC1 activation. Thus, these findings integrate the role of the NPC with mTORC1 by demonstrating that the presence of RagC in the nucleus is mechanistically important.
